Study of NKF-PEG compared to Neulasta in healthy men
This study tests a new medicine called NKF-PEG, which is similar to Neulasta (a drug that helps boost white blood cells after chemotherapy). It is being tested in healthy men to see how the body processes it and to check for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Men aged 18 to 55 years
- Weight at least 50 kg (110 lbs) and body mass index between 18.5 and 30
- Willing to use birth control (or abstain from sex) for 90 days after the study
- No major medical problems, infections, or allergies to E. coli products
- No tattoos, scars, or skin conditions at the injection site
- No alcohol abuse in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a drug called Efbemalenograstim Alfa can help prevent a serious drop in white blood cells (febrile neutropenia) during chemotherapy. It is for patients with solid tumors who have a high or intermediate risk of this condition.
This study tests whether a medicine called pegfilgrastim can help prevent dangerously low white blood cell counts in women with triple-negative breast cancer receiving a specific chemotherapy combination. Low white blood cells increase infection risk, so this medicine may help patients stay safer during treatment.
This early study tests a new type of protein replacement therapy for healthy volunteers. The purpose is to see if it is safe and how the body handles it.
This study tests how safe and tolerable a new drug, KSHN001034, is in healthy women who have gone through menopause. It involves multiple doses to see how your body processes the medicine.
This trial tests a medication that aims to reduce the risk of dangerously low white blood cell counts (neutropenia) after chemotherapy combined with immunotherapy for certain advanced lung or esophageal cancers. It may help prevent infections and other complications, making treatment safer.
This study tests a new experimental medicine called PMG1016 to see how safe it is and how it moves through the body in healthy volunteers. You'll receive a single dose and have your blood checked and heart monitored to make sure the medicine is well-tolerated.
Hear when a new Healthy Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.